A phase 3 open-label extension study (OLES) to evaluate long-term safety/tolerability of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) in patients with Parkinson's disease (PD).
No takes yet. Share an insight, caveat, or question.
Fung et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: